Mesoblast Receives Clearance to Begin Phase 2 Clinical Trial of Mesenchymal Precursor Cells in Diabetic Nephropathy
25 juin 2013 21h12 HE
|
Mesoblast
NEW YORK, N.Y., June 25, 2013 (GLOBE NEWSWIRE) -- Key Points:∙ Mesoblast has received ethics approvals to begin a clinical trial of its proprietary allogeneic, or “off-the-shelf”,...
Key Mesenchymal Precursor Cell Patent Granted in Japan
04 juin 2013 20h47 HE
|
Mesoblast
NEW YORK and MELBOURNE, Australia, June 4, 2013 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today announced that it has been granted a key patent by the...
MESOBLAST'S PRECLINICAL TRIAL RESULTS OF INTRACORONARY CELL THERAPY PUBLISHED IN CIRCULATION RESEARCH
14 mai 2013 21h04 HE
|
Mesoblast
NEW YORK, May 14, 2013 (GLOBE NEWSWIRE) -- Mesoblast's preclinical trial results of its allogeneic, or "off-the-shelf", Mesenchymal Precursor Cells (MPC) delivered by intracoronary infusion in acute...
MESOBLAST REPORTS POSITIVE INTERIM RESULTS IN PHASE 2 TRIAL OF PROPRIETARY ADULT STEM CELLS FOR INTERVERTEBRAL DISC REPAIR
22 avr. 2013 04h07 HE
|
Mesoblast
Mesoblast's Phase 2 trial of allogeneic, or "off-the-shelf", Mesenchymal Precursor Cells (MPCs) injected into damaged intervertebral discs has now completed six-month follow-up for all 100...
MESOBLAST CHIEF EXECUTIVE HONOURED AT THE VATICAN WITH INAUGURAL PONTIFICAL AWARD FOR INNOVATION
12 avr. 2013 03h49 HE
|
Mesoblast
NEW YORK and MELBOURNE, Australia, April 12, 2013 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB, USOTC:MBLTY) is pleased to announce that its Chief Executive Professor...
Mesoblast Completes A$170m Private Placement
13 mars 2013 23h08 HE
|
Mesoblast
MELBOURNE, Australia, March 13, 2013 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB) (USOTC:MBLTY) today announced that it has completed a private placement of its...
FDA Agreement on Mesoblast's Use of Singapore Manufacturing Facility for Clinical Trial Production of Proprietary Mesenchymal Precursor Cells
12 févr. 2013 20h28 HE
|
Mesoblast
MELBOURNE, Australia, Feb. 12, 2013 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (OTC ADR:MBLTY) today announced that United States Food and Drug Administration (FDA) is in agreement for Mesoblast...
Mesoblast Reports Half-Year 2013 Financial Results
10 févr. 2013 23h40 HE
|
Mesoblast
NEW YORK, Feb. 10, 2013 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (OTC ADR:MBLTY) today provided its half-year 2013 financial results, as well as a strategic update on the key areas of product...
Key Mesenchymal Precursor Cell Patents Granted in United States and China
06 févr. 2013 19h40 HE
|
Mesoblast
MELBOURNE, Australia, Feb. 6, 2013 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB) (USOTC:MBLTY) today announced that it has been granted three key new patents by the...
Mesoblast Receives FDA Clearance for Phase 2 Clinical Trial of Mesenchymal Precursor Cells in Patients With Active Rheumatoid Arthritis
29 janv. 2013 20h25 HE
|
Mesoblast
Key Points:
Mesoblast receives clearance from United States Food and Drug Administration (FDA) to begin Phase 2 trial of proprietary allogeneic, or "off-the-shelf", Mesenchymal Precursor Cells...